Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982;13(Suppl 1):115S–122S. doi: 10.1111/j.1365-2125.1982.tb01899.x

Alternatives to β-blockade in therapy of hypertension with angina pectoris

Role of nifedipine or of labetalol

L H Opie, D White, J Lee, W F Lubbe
PMCID: PMC1401829  PMID: 7093094

Abstract

1 Patients with combined hypertension and angina pectoris may represent a therapeutic dilemma, with the angina being refractory to conventional β-blockade.

2 The added benefit of peripheral vasodilation in control of blood pressure is documented in the case of nifedipine.

3 Improved blood pressure control by added nifedipine may not be accompanied by decreased severity of angina pectoris, emphasizing the complex causation of the angina in such patients.

4 The clinically proven added α-blocking activity of labetalol distinguishes labetalol from other β-blockers. However, the suggested benefits of the added α-activity in patients with hypertension and angina remain to be proven by further trials in patients.

Full text

PDF
115S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anastassiades C. J. Nifedipine and beta-blocker drugs. Br Med J. 1980 Nov 8;281(6250):1251–1252. doi: 10.1136/bmj.281.6250.1251-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bailey R. R. Labetalol in the treatment of patients with hypertension and renal function impairment. Br J Clin Pharmacol. 1979;8(Suppl 2):135S–140S. [PMC free article] [PubMed] [Google Scholar]
  3. Besterman E. M., Spencer M. Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients. Br J Clin Pharmacol. 1979;8(Suppl 2):205S–209S. [PMC free article] [PubMed] [Google Scholar]
  4. Fagard R., Amery A., Reybrouck T., Lijnen P., Billiet L. Response of the systemic and pulmonary circulation to alpha- and beta-receptor blockade (labetalol) at rest and during exercise in hypertensive patients. Circulation. 1979 Dec;60(6):1214–1217. doi: 10.1161/01.cir.60.6.1214. [DOI] [PubMed] [Google Scholar]
  5. Fitzgerald J. D., Ruffin R., Smedstad K. G., Roberts R., McAinsh J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol. 1978 May 17;13(2):81–89. doi: 10.1007/BF00609750. [DOI] [PubMed] [Google Scholar]
  6. Greenslade F. C., Tobia A. J., Madison S. M., Krider K. M., Newquist K. L. Labetalol binding to specific alpha- and beta-adrenergic sites in vitro and its antagonism of adrenergic responses in vivo. J Mol Cell Cardiol. 1979 Aug;11(8):803–811. doi: 10.1016/0022-2828(79)90405-x. [DOI] [PubMed] [Google Scholar]
  7. Himori N., Ono H., Taira N. Simultaneous assessment of effects of coronary vasodilators on the coronary blood flow and the myocardial contractility by using the blood-perfused canine papillary muscle. Jpn J Pharmacol. 1976 Aug;26(4):427–435. doi: 10.1254/jjp.26.427. [DOI] [PubMed] [Google Scholar]
  8. Keys A., Taylor H. L., Blackburn H., Brozek J., Anderson J. T., Simonson E. Mortality and coronary heart disease among men studied for 23 years. Arch Intern Med. 1971 Aug;128(2):201–214. doi: 10.1001/archinte.1971.00310200037002. [DOI] [PubMed] [Google Scholar]
  9. Kilcoyne M. M. The developing phase of primary hypertension. II. Treatment. Mod Concepts Cardiovasc Dis. 1980 May;49(5):25–30. [PubMed] [Google Scholar]
  10. Lassvik C. T., Areskog N. H. Angina in cold environment. Reactions to exercise. Br Heart J. 1979 Oct;42(4):396–401. doi: 10.1136/hrt.42.4.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Levene D. L., Freeman M. R. Alpha-adrenoceptor-mediated coronary artery spasm. JAMA. 1976 Aug 30;236(9):1018–1022. [PubMed] [Google Scholar]
  12. Lubbe W. F., White D. A. Labetalol in hypertensive patients with angina pectoris: beneficial effect of combined alpha- and beta-adrenoreceptor blockade. Clin Sci Mol Med Suppl. 1978 Dec;4:283s–286s. doi: 10.1042/cs055283s. [DOI] [PubMed] [Google Scholar]
  13. Lund-Johansen P. Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin. Br J Clin Pharmacol. 1979;8(Suppl 2):107S–111S. [PMC free article] [PubMed] [Google Scholar]
  14. Lynch P., Dargie H., Krikler S., Krikler D. Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination. Br Med J. 1980 Jul 19;281(6234):184–187. doi: 10.1136/bmj.281.6234.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. McNeil J. J., Louis W. J. A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Br J Clin Pharmacol. 1979;8(Suppl 2):163S–166S. [PMC free article] [PubMed] [Google Scholar]
  16. Mehta J., Cohn J. N. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation. 1977 Feb;55(2):370–375. doi: 10.1161/01.cir.55.2.370. [DOI] [PubMed] [Google Scholar]
  17. Nestel P. J. Blood-pressure and catecholamine excretion after mental stress in labile hypertension. Lancet. 1969 Apr 5;1(7597):692–694. doi: 10.1016/s0140-6736(69)92645-2. [DOI] [PubMed] [Google Scholar]
  18. Olivari M. T., Bartorelli C., Polese A., Fiorentini C., Moruzzi P., Guazzi M. D. Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation. 1979 May;59(5):1056–1062. doi: 10.1161/01.cir.59.5.1056. [DOI] [PubMed] [Google Scholar]
  19. Opie L. H., White D. A. Adverse interaction between nifedipine and beta-blockade. Br Med J. 1980 Nov 29;281(6253):1462–1462. doi: 10.1136/bmj.281.6253.1462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ricci D. R., Orlick A. E., Cipriano P. R., Guthaner D. F., Harrison D. C. Altered adrenergic activity in coronary arterial spasm: insight into mechanism based on study of coronary hemodynamics and the electrocardiogram. Am J Cardiol. 1979 Jun;43(6):1073–1079. doi: 10.1016/0002-9149(79)90137-1. [DOI] [PubMed] [Google Scholar]
  21. Richards D. A., Prichard B. N., Boakes A. J., Tuckman J., Knight E. J. Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J. 1977 Jan;39(1):99–106. doi: 10.1136/hrt.39.1.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Richards D. A., Tuckman J., Prichard B. N. Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol. 1976 Oct;3(5):849–855. doi: 10.1111/j.1365-2125.1976.tb00637.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Richardson P. J., Hill L. S. Relationship between hypertension and angina pectoris. Br J Clin Pharmacol. 1979;7 (Suppl 2):249S–253S. doi: 10.1111/j.1365-2125.1979.tb04697.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Safar M. E., Weiss Y. A., London G. M., Chau N. P. Differences in the mechanisms of borderline and permanent hypertension. Postgrad Med J. 1977;53 (Suppl 3):35–39. [PubMed] [Google Scholar]
  25. Schiffer F., Hartley L. H., Schulman C. L., Abelmann W. H. Evidence for emotionally-induced coronary arterial spasm in patients with angina pectoris. Br Heart J. 1980 Jul;44(1):62–66. doi: 10.1136/hrt.44.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Trust P. M., Rosei E. A., Brown J. J., Fraser R., Lever A. F., Morton J. J., Robertson J. I. Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):799–803. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES